Literature DB >> 26010519

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.

Daniel Verduzco1, Keith T Flaherty2, Keiran S M Smalley1,3.   

Abstract

Entities:  

Keywords:  BRAF; melanoma; oxidative phosphorylation; resistance

Mesh：

Substances：

Year:  2015        PMID： 26010519      PMCID： PMC4537671          DOI： 10.1111/exd.12763

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


× No keyword cloud information.
  7 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.

Authors:  Elisabeth Livingstone; Suzanne Swann; Carmen Lilla; Dirk Schadendorf; Alexander Roesch
Journal:  Exp Dermatol       Date:  2015-05-08       Impact factor: 3.960

Review 3.  Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Authors:  Kristel Kemper; Pauline L de Goeje; Daniel S Peeper; Renée van Amerongen
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

4.  Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.

Authors:  Chenfang Dong; Tingting Yuan; Yadi Wu; Yifan Wang; Teresa W M Fan; Sumitra Miriyala; Yiwei Lin; Jun Yao; Jian Shi; Tiebang Kang; Pawel Lorkiewicz; Daret St Clair; Mien-Chie Hung; B Mark Evers; Binhua P Zhou
Journal:  Cancer Cell       Date:  2013-02-28       Impact factor: 31.743

5.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Authors:  Tiffany J Parmenter; Margarete Kleinschmidt; Kathryn M Kinross; Simon T Bond; Jason Li; Mohan R Kaadige; Aparna Rao; Karen E Sheppard; Willy Hugo; Gulietta M Pupo; Richard B Pearson; Sean L McGee; Georgina V Long; Richard A Scolyer; Helen Rizos; Roger S Lo; Carleen Cullinane; Donald E Ayer; Antoni Ribas; Ricky W Johnstone; Rodney J Hicks; Grant A McArthur
Journal:  Cancer Discov       Date:  2014-01-27       Impact factor: 39.397

6.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

7.  Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Authors:  Ping Yuan; Koichi Ito; Rolando Perez-Lorenzo; Christina Del Guzzo; Jung Hyun Lee; Che-Hung Shen; Marcus W Bosenberg; Martin McMahon; Lewis C Cantley; Bin Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205
  7 in total
  4 in total

Review 1.  Targeting ERK beyond the boundaries of the kinase active site in melanoma.

Authors:  Rachel M Sammons; Ranajeet Ghose; Kenneth Y Tsai; Kevin N Dalby
Journal:  Mol Carcinog       Date:  2019-06-12       Impact factor: 4.784

2.  Persister state-directed transitioning and vulnerability in melanoma.

Authors:  Heike Chauvistré; Batool Shannan; Sheena M Daignault-Mill; Robert J Ju; Daniel Picard; Stefanie Egetemaier; Renáta Váraljai; Christine S Gibhardt; Antonio Sechi; Farnusch Kaschani; Oliver Keminer; Samantha J Stehbens; Qin Liu; Xiangfan Yin; Kirujan Jeyakumar; Felix C E Vogel; Clemens Krepler; Vito W Rebecca; Linda Kubat; Smiths S Lueong; Jan Forster; Susanne Horn; Marc Remke; Michael Ehrmann; Annette Paschen; Jürgen C Becker; Iris Helfrich; Daniel Rauh; Markus Kaiser; Sheraz Gul; Meenhard Herlyn; Ivan Bogeski; José Neptuno Rodríguez-López; Nikolas K Haass; Dirk Schadendorf; Alexander Roesch
Journal:  Nat Commun       Date:  2022-06-01       Impact factor: 17.694

Review 3.  Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Maria Tsironi
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-06

4.  Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.

Authors:  Paola Corazao-Rozas; Pierre Guerreschi; Fanny André; Pierre-Elliott Gabert; Steve Lancel; Salim Dekiouk; Delphine Fontaine; Meryem Tardivel; Ariel Savina; Bruno Quesnel; Laurent Mortier; Philippe Marchetti; Jérome Kluza
Journal:  Oncotarget       Date:  2016-06-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.